Robert Bazemore Buys Shares of Ardelyx, Inc. $ARDX
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Robert Bazemore, insider at Ardelyx, Inc. ($ARDX), bought 26,455 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Ardelyx, Inc. Stock Up 53.3%
Shares of Ardelyx, Inc. ($ARDX) traded around $5.84 on Thursday, up 53.3% for the day.
Ardelyx, Inc. Earnings
Analysts Set New Price Targets
About Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Get Ardelyx, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ARDX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.